



## REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

**APPLICATION NO.**

P-4901

Petits, Ronald et al.

**FILING DATE**

June 29, 2000

GROUP

3748

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

BT	AA	Bronaugh RL, Stewart RF, Congdon ER. Methods for in Vitro Percutaneous Absorption Studies. II. Animal Models for Human Skin. <i>Toxicol and Applied Pharmacol.</i> 1982 Mar 15;62(3):481-8.
BT	AB	Corbo M, Liu JC, Chien YW. Transdermal Controlled Delivery of Propranolol from a Multilaminate Adhesive Device. <i>Pharm Res.</i> 1989 Sep;6(9):753-8.

~~RECEIVED~~

NOV 01 2002

# TECHNOLOGY CENTER R3700

**EXAMINER**

BINH TRAN

**DATE CONSIDERED**

01/05/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

O I P E

S

Please type a plus sign (+) inside this box → +

NOV 12 2002

S

A

F

P

T

A

E

M

T

R

M

P

A

T

M

E

R

S

T

E

R

C

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

R

E

NOV 12 2002  
PATENT & TRADEMARK OFFICE  
O I P E  
Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/606,909
Sheet	2	of	2	Filing Date	June 29, 2000
				First Named Inventor	PETTIS <i>et al.</i>
				Group Art Unit	3748
				Examiner Name	Binh Q. TRAN
				Attorney Docket Number	P-4901

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	BL	E. AUTRET <i>et al.</i> , Therapie 1991, 46 : 5-8.		
	BM	BRESSOLLE <i>et al.</i> , "A Weibull Distribution Model for Intradermal Administration of Ceftazidime", Journal of Pharmaceutical Sciences, Vol. 82, No. 11, November 1993, pps. 1175-1178.		
	BN	HENRY <i>et al.</i> , "Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery", Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998, pps. 922-925.		
	BO	KAUSHIK <i>et al.</i> , "Transdermal Protein Delivery Using Microfabricated Microneedles", Oct/Nov 1999 (1 page).		
	BP	BURKOTH <i>et al.</i> , "Transdermal and Transmucosal Powered Drug Delivery", Critical Review™ in Therapeutic Drug Carrier Systems, 16 (4), (1999), pps. 331-384.		
	BQ	MCALLISTER <i>et al.</i> , "Three-Dimensional Hollow Microneedle and Microtube Arrays", Conference: Solid-State Sensors and Actuators Transducers-Conference, 1999; 10 <sup>th</sup> , Vol. 12, pp 1098-1103.		
	BR	MCALLISTER <i>et al.</i> , "Solid and Hollow Microneedles for Transdermal Protein Delivery", Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., 26 (Revised July 1999) Controlled Release Society, Inc. pp. 192-193		
	BS	SEBASTIEN <i>et al.</i> , "Microfabricated Needles: A Novel Approach to Transdermal Drug Delivery", Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998, pp. 922-925		
		RECEIVED NOV 13 2002 NOV 13 2002 R3700 TECHNOLOGY CENTER R3700		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## Sheet

1

of

4

***Complete if Known***

<b>Application Number</b>	09/606,909
<b>Filing Date</b>	June 29, 2000
<b>First Named Inventor</b>	Pettis, et al.
<b>Art Unit</b>	3748
<b>Examiner Name</b>	Binh Q. Tran
<b>Attorney Docket Number</b>	P-4901

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner  
Signature

BINH TRAN

Date Considered

01/05/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

\* The reference has been cited in PTO-892

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DEC 18 2002  
U.S. TRADES

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

4

## Complete if Known

Application Number	09/606,909
Filing Date	June 29, 2000
First Named Inventor	Pettis, et al.
Group Art Unit	3748
Examiner Name	Binh Q. Tran
Attorney Docket Number	P-4901

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
BT	AF	AGRAWAL, et al., "Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in Mice", Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 7595-7599, September 1991 Medical Sciences
	AG	AUTRET, et al., "Comparison of Pharmacokinetics and tolerance of Calcitonine administered by Intradermal or Subcutaneous Route", Fundamental Clinical Pharmacology, Vol. 3, No. 2, pp 170-171, 1989
	AH	BENONI, et al., "Distribution of Ceftazidime in Ascitic Fluid", Antimicrobial Agents and Chemotherapy, Vol. 25, No. 6, June 1984, pp. 760-763
	AI	BICKERS, et al., editors, "Clinical Pharmacology of Skin Disease", pp. 57-90, Churchill Livingstone, Inc., 1984
	AJ	BOCCI, et al., "The Lymphatic Route. IV. Pharmacokinetics of Human Recombinant Interferon a2 and Natural Interferon $\beta$ Administered Intradermally in Rabbits", International Journal of Pharmaceutics, 32, 1986, pp. 103-110 Elsevier Science Publishers B.V. (Biomedical Division)
	AK	CALLEN, "Intralesional Corticosteroids", Journal of the American Academy of Dermatology, University of Louisville School of Medicine, pp. 149-151, 1981
	AL	COSSUM, et al., "Disposition of the C-Labeled Phosphorothioate Oligonucleotide ISIS 2105 after Intravenous Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 1181-1190, Vol. 267, No. 3, 1993
	AM	COSSUM, et al., "Pharmacokinetics of C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105 after Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 89-94, Vol. 269, No. 1, 1994
	AN	CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts", Clinical Pharmacology & Therapeutics, pp. 641-646, Vol. 56, No. 6, Part 1, December 1994
	AO	FIROOZ, et al., "Benefits and Risks of Intralesional Corticosteroid Injection in the Treatment of Dermatological Diseases", pp. 363-370, Vol. 20, No. 5, Clinical and Experimental Dermatology, Blackwell Science Ltd, September 1995
✓	AP	GOODARZI, et al., "Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleotides in Mice", "Biopharmaceutics & Drug Disposition, pp. 221-227, Vol. 13, No. 3, John Wiley & Sons, Ltd, April 1992

RECEIVED

DEC 23 2002

TECHNOLOGY CENTER R3700

Examiner Signature

BINH TRAN

Date Considered

01/05/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

4

## Complete if Known

Application Number	09/606,909
Filing Date	June 29, 2000
First Named Inventor	Pettis, et al.
Group Art Unit	3748
Examiner Name	Binh Q. Tran
Attorney Docket Number	P-4901

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BS	AQ	HAYNES, et al., "Ultra-long-duration Local Anesthesia Produced by Injection of Lecithin-coated Methoxyflurane Microdroplets", Anesthesiology, Vol. 63, No. 5, pp. 490-499, Nov. 1985	
	AR	JAKOBSON, et al., "Variations in the Blood Concentration of 1, 1,2-Trichloroethane by Percutaneous Absorption and Other Routes of Administration in the Guinea Pig", Vol. 41, No. 5, pp. 497-506, Acta Pharmacologica et Toxicologica, November 1977	
	AS	JARRATT, et al., "The Effects of Intradermal Steroids on the Pituitary-Adrenal Axis and the Skin", The Journal of Investigative Dermatology, Vol. 62, No. 4, pp. 463-466, 1974	
	AT	KIRKPATRICK, et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man", Vol. 67, No. 3A, Anesthesiology, September 1987	
	AU	LEROY, et al., "Pharmacokinetics of Ceftazidime in Normal and Uremic Subjects", Antimicrobial Agents and Chemotherapy, Vol. 25, No. 5, pp. 638-642, May 1984	
	AV	MCGUGAN, et al., "Adrenal Suppression from Intradermal Triamcinolone", The Journal of Investigative Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963	
	AW	SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981	
	AX	SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988	
	AY	SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study", Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979	
	AZ	WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975	
↓	BA	WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.	

RECEIVED

DEC 23 2002

Examiner  
Signature

BINH TRAN

Date  
Considered

TECHNOLOGY CENTER 10700  
07/05/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449B/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Shee

4

10

4

**Complete if Known**

<b>Application Number</b>	09/606,909
<b>Filing Date</b>	June 29, 2000
<b>First Named Inventor</b>	Pettis, et al.
<b>Group Art Unit</b>	3748
<b>Examiner Name</b>	Binh Q. Tran
<b>Attorney Docket Number</b>	P-4901

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner  
Signature

BINH TRAN

Date  
Considered

01/05/03

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1** Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.